Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arTreg-CSB
- Development stage
- Phase 2
- Lead developer
- Massachusetts General Hospital
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
arTreg-CSB is an autologous regulatory T cell (Treg) therapy developed for use in solid organ transplantation, specifically to facilitate immunosuppression withdrawal in liver transplant recipients. The product consists of ex vivo expanded regulatory T cells derived from the patient, which are then infused back into the recipient. The primary mechanism is immune modulation through enhancement of immune tolerance, aiming to reduce or eliminate the need for long-term immunosuppressive drugs and promote operational tolerance of the transplanted organ[6][8]. This approach leverages the natural suppressive function of Tregs to prevent graft rejection while minimizing adverse effects associated with chronic immunosuppression.
- Brand names
- arTreg-CSB
- Other names
- arTreg-CSB
Beyond the preview
Go deeper on arTreg-CSB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arTreg-CSB.